Deals
-
Courtesy of Hims & Hers
Obesity drugsNovo, Hims reach deal to sell GLP-1 drugs together
The agreement ends a messy dispute that began when the telehealth firm attempted to sell a compounded form of Novo’s Wegovy pill at a cheaper price.
By Ben Fidler • March 9, 2026 -
Getty Images
Servier to build cancer drug pipeline with $2.5B purchase of Day One
The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved therapy for certain hard-to-treat brain tumors that affect children.
By Jacob Bell • March 6, 2026 -
Scott Olson via Getty Images
Obesity drugsLilly targets employers in new bid to broaden access to obesity drugs
A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.
By Jonathan Gardner • March 5, 2026 -
Courtesy of Teva Pharmaceutical
Blackstone puts $400M into Teva, Sanofi gut disease drug
The deal adds to a growing biotech presence for Blackstone and supports testing of a drug competing with rival therapies from Merck and Roche.
By Jonathan Gardner • March 4, 2026 -
Courtesy of GSK
GSK to acquire 35Pharma in $950M deal for cardiovascular drug
The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.
By Kristin Jensen • Feb. 25, 2026 -
Getty Images
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.
By Delilah Alvarado • Feb. 24, 2026 -
Permission granted by Gilead Sciences
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.
By Ben Fidler • Feb. 23, 2026 -
Getty Images
Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6
The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.
By Kristin Jensen • Feb. 18, 2026 -
Getty Images
Immune resetLilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.
By Jonathan Gardner • Feb. 9, 2026 -
Permission granted by Iambic Therapeutics
Emerging biotechTakeda, Iambic partner in latest pharma AI push
“The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug development, said Takeda research chief Andy Plump.
By Jacob Bell • Feb. 9, 2026 -
Alamy
Amgen gives up on its once-prized eczema drug
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.
By Jonathan Gardner • Jan. 30, 2026 -
Alamy
China competitionAstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC
The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.
By Ben Fidler • Jan. 30, 2026 -
Courtesy of BMS
Bristol Myers buys into Janux’s ‘masked’ T cell engagers
Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.
By Delilah Alvarado • Jan. 22, 2026 -
Permission granted by GSK
GSK to buy Rapt in $2.2B deal for food allergy drug
The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.
By Kristin Jensen • Jan. 20, 2026 -
Courtesy of Boston Scientific
Boston Scientific to acquire Penumbra for $14.5B
With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.
By Elise Reuter • Jan. 15, 2026 -
Getty Images
Obesity drugsAlveus launches with $160M to advance MariTide-like obesity drug
The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.
By Jonathan Gardner • Jan. 8, 2026 -
Scott Olson via Getty Images
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs
The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an array of conditions.
By Jonathan Gardner • Updated Jan. 8, 2026 -
Alamy
Emerging biotech
Amgen buys protein-degrading startup Dark Blue for up to $840M
The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications.
By Gwendolyn Wu • Jan. 6, 2026 -
Getty Images
BioMarin to buy rare disease drugmaker Amicus for $4.8B
Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies that generated nearly $450 million over the first nine months of this year.
By Jacob Bell • Dec. 19, 2025 -
Getty Images
Emerging biotechSobi snaps up gout drug in $950M deal for startup Arthrosi
The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist despite initial therapy.
By Ben Fidler • Dec. 14, 2025 -
Mario Tama via Getty Images
China competitionPfizer dips into China for another try at an obesity pill
A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.
By Kristin Jensen • Dec. 9, 2025 -
Getty Images
Emerging biotechThe ‘clever’ tool increasingly getting bigger biotech deals signed
A decades-old way to bridge buyers and sellers on price, contingent value rights have recently seen an uptick in use due to a turbulent biotech market.
By Jacob Bell • Dec. 2, 2025 -
Courtesy of Regeneron Pharmaceuticals
Gene editingRegeneron inks gene editing deal with startup Tessera
The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.
By Delilah Alvarado • Dec. 1, 2025 -
Permission granted by Gilead Sciences
Gilead scoops up a preclinical cancer program
The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”
By Kristin Jensen • Nov. 25, 2025 -
Jacob Bell/BioPharma Dive
Emerging biotechBiogen strikes deal with Versant-backed biotech to expand immune portfolio
Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority immunological targets."
By Delilah Alvarado • Nov. 24, 2025
